X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Pelosi’s radical plan would leave patients with sickle cell disease behind

By Tom Wilbur  |    November 14, 2019
Sickle cell disease (SCD) is the most commonly inherited genetic blood disorder, affecting nearly 100,000 children and adults in the United States. Three million Americans carry the sickle cell...   Read More

R&D Focus: It takes an ecosystem to deliver innovative new therapies

By Richard Moscicki, M.D.  |    November 14, 2019
We are living in a new era of medicine where innovations are transforming our ability to attack the cause of a disease, not just the symptoms. Today, concepts, such as cell and gene therapies, ...   Read More

PhRMA submission to 2020 National Trade Estimate Report: Urgent action required to protect U.S. biopharmaceutical innovation

By Douglas Petersen  |    November 8, 2019
International trade policy plays a critical role in ensuring that the U.S. biopharmaceutical industry can continue to develop and provide both American and international patients with access to...   Read More

Pelosi’s radical plan would leave patients with rare pediatric diseases behind

By Tom Wilbur  |    November 7, 2019
There are about 7,000 rare diseases and half of these affect children. According to the National Institutes of Health (NIH), 30 million Americans, or 10 percent of the population, have one of the...   Read More

Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter

By Guest Contributor  |    November 7, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy

By Tom Wilbur  |    November 4, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections, including patents, to maintain its role as the global leader in biopharmaceutical...   Read More

New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country

By Katie Koziara  |    November 4, 2019
A new analysis from Xcenda applied the Institute for Clinical and Economic Review’s (ICER) value assessments to state Medicaid programs in California, Massachusetts, Maryland, Nevada and New York....   Read More

What they are saying: Negative impact of Pelosi’s plan on biopharmaceutical innovation

By Tom Wilbur  |    October 31, 2019
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that would be the wrong approach for patients, the U.S. health care system and the economy.   Read More

Pelosi’s radical plan leaves lung cancer patients behind

By Tom Wilbur  |    October 23, 2019
Lung cancer is the second most common form of cancer in men and women and the leading cause of cancer-related deaths in the United States. In 2019 alone, there will be an estimated 228,000 new...   Read More

Guest post: Sharing discounts and rebates is the right thing to do

By Guest Contributor  |    October 21, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates